Morning Consult

Morning Consult Health: Sanders Outlines Plans for $200 Billion Health Care Package

Morning Consult sent this email to their subscribers on May 17, 2023.

WV MORNING CONSULT
 

Health

Essential health care industry news & intel to start your day.
May 17, 2023
Twitter Email
 

Today's Top News

  • Sen. Bernie Sanders (I-Vt.) plans to use his position as leader of the Senate Health, Education, Labor and Pensions Committee to pursue a nearly $200 billion plan to improve the U.S. health system, including tens of billions of dollars to address health care staffing shortages. Over five years, the plan would provide $130 billion to community health centers and $60 billion to grow the health workforce, with $15 billion earmarked for graduate medical programs, Sanders said in an interview. (Politico)
  • AstraZeneca PLC said it left the powerful pharmaceutical industry lobbying group PhRMA, following Teva Pharmaceuticals Industries Ltd.'s decision to leave in February and AbbVie Inc.'s exit in December 2022. AstraZeneca said the decision came after reevaluating whether trade group memberships are "productive and effective," stating that the company will continue to lobby state and federal lawmakers but are "changing how we do it." (Stat News)
  • The 5th U.S. Circuit Court of Appeals will hear oral arguments today for the controversial lawsuit that challenges the Food and Drug Administration's approval of the abortion pill mifepristone, putting the fate of access to the medication in the hands of three judges with a history of supporting abortion restrictions. (The Associated Press) Meanwhile, North Carolina's Republican-controlled state legislature overrode Gov. Roy Cooper's (D) veto of a 12-week abortion ban, allowing the law to now take effect. (Axios)
  • The higher mortality rate for Black Americans led to 1.63 million excess deaths between 1999 to 2020 compared with white Americans, according to a new JAMA study. Clyde Yancy, an author of the study and chief of cardiology at Northwestern University's Feinberg School of Medicine, said that the high mortality rates have more to do with the United States' history of discrimination than with genetics, adding that it is "very clear that we have an uneven distribution of health." (KFF Health News)

Worth watching today:

  • Financial Times's "U.S. Pharma and Biotech Summit" continues. Today's speakers include Amgen Inc. CEO Robert A. Bradway and Roche Pharmaceuticals CEO Teresa Graham.
  • The Duke-Margolis Center hosts its in Washington, D.C. Speakers include Elizabeth Fowler, director of the Center for Medicare & Medicaid Innovation, Ashish Jha, the White House's COVID-19 response coordinator, and Meena Seshamani, director of the Center for Medicare.
  • House Ways and Means Health Subcommittee hearing: "Why Health Care is Unaffordable: Anticompetitive and Consolidated Markets."
 

Chart Review

Change in cancer death rates by congressional district Change in the number of deaths per 100k residents; 1996-2003 compared to 2012-2020 E -50% -40% -30% -20% KY-05 b Data: American Cancer Society. Note: Death rate is computed as the average of the male and female rates. Map: Erin DavisAxios Visuals
 
 

What Else You Need to Know

Coronavirus
 

Moderna hits back at Alnylam's 'baseless' patent infringement claims

Zoey Becker, Fierce Pharma

After Alnylam levied patent infringement claims against Moderna last year, the mRNA specialist is hitting back. In a pair of countersuits, Moderna claims Alnylam "baselessly seeks to profit" from Moderna's inventions.

 

As COVID-19 recedes, payers face changed coverage landscape

Frank Diamond, Fierce Healthcare 

There will never be a return to a pre-pandemic normal in terms of what health insurers, self-insured employers and other payers must cover, but they will in some ways be less burdened as COVID-19 recedes, according to Jeff Levin-Scherz, M.D., the population health leader for health and benefits in North America at Willis Towers Watson.

 

AstraZeneca Investors Lose Appeal of Covid Shot Suit's Dismissal

Martina Barash, Bloomberg Law 

AstraZeneca PLC investors failed to show the drugmaker misled them about its coronavirus vaccine testing process, the Second Circuit affirmed Tuesday.

 
General
 

The one abortion law Democrats aren't rushing to repeal

Megan Messerly and Alice Miranda Ollstein, Politico

As legislative sessions come to a close, state lawmakers are divided over whether children and teenagers should be able to have an abortion without telling their parents.

 

Pfizer RSV vaccine for infants has 'generally favorable' safety data, FDA staff say

Annika Kim Constantino, CNBC

The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday when a panel of external advisors to the agency will discuss whether to recommend full approval of the RSV shot.

 

Drug Shortages Near an All-Time High, Leading to Rationing

Christina Jewett, The New York Times

A worrisome scarcity of cancer drugs has heightened concerns about the troubled generic drug industry. Congress and the White House are seeking ways to address widespread supply problems.

 

Young Americans Are Dying at Alarming Rates, Reversing Years of Progress

Janet Adamy, The Wall Street Journal

For decades, advances in healthcare and safety steadily drove down death rates among American children. In an alarming reversal, rates have now risen to the highest level in nearly 15 years, particularly driven by homicides, drug overdoses, car accidents and suicides.

 

Comstock Act, 150-year-old law, may determine U.S. access to abortion 

Dan Diamond and Ann E. Marimow, The Washington Post 

The future of abortion access in the United States may soon depend on how courts interpret a 150-year-old law that hadn't been applied for nearly a century — and whose author originally intended for some abortions to remain legal.

 

Republicans weigh changes to law meant to protect abortion access 

Michael Macagnone, Roll Call 

The chairman of a House Judiciary subcommittee said Tuesday that Republicans could pursue changes to a 1994 law meant to protect access to reproductive health care clinics.

 

Republican abortion debate inches toward resolution in South Carolina

James Pollard, The Associated Press

Abortions would be almost entirely banned after about six weeks of pregnancy under a bill debated early into Wednesday morning by the South Carolina House in a development that follows months of Republicans in the chamber insisting instead on a near-total ban that the state Senate recently rejected.

 

Suspected deadly fungal infections linked to surgery in Mexico

Lena H. Sun, The Washington Post

The CDC issued a travel advisory after five women developed meningitis after surgical procedures in the border city of Matamoros.

 

Walgreens sees benefit from CVS exiting clinical trial business

Anjalee Khemlani, Yahoo Finance 

Walgreens is already benefiting from CVS winding down its efforts to conduct clinical trials in its retail locations.

 

Chronic pain is more common than diabetes or depression. Better treatments are emerging.

Aria Bendix, NBC News

People are developing new cases of chronic pain at higher rates than new diagnoses of diabetes, depression or high blood pressure, according to a study published Tuesday.

 

Weight-loss drugs and surgery for kids leave parents with tough decisions 

Yuki Noguchi, NPR News

New drugs like semaglutide — approved for weight loss under the brand Wegovy — tamp down hunger and boost metabolism; adolescent bariatric surgery achieves similar results. Both treatments were added early this year to the American Academy of Pediatrics' recommended treatment guidelines for children as young as 12 or 13 — acknowledging the increasing threat of the disease in children.

 

Cops say they're being poisoned by fentanyl. Experts say the risk is 'extremely low'

Brian Mann, NPR News

Police officers regularly report being poisoned or overdosing after encountering trace amounts of fentanyl on the job. Experts say it's not happening.

 

NIH seeks to unlock secrets of how our bodies respond to food

Tina Reed, Axios 

Federal researchers are launching a major study of how genes, lifestyle and other factors influence how the body responds to diet, to come up with better interventions when it comes to what we eat.

 

The fraught fight to stop the trans healthcare bans

Emma Hurt et al., Axios

Across the country, Democratic lawmakers in GOP states have struggled to stop an onslaught of bills restricting gender-affirming health care for transgender minors.

 

How a Few Stories of Regret Fuel the Push to Restrict Gender Transition Care 

Maggie Astor, The New York Times 

In the campaign to ban gender therapies for minors, Republicans have amplified a group of activists who no longer identify as transgender, overriding objections from transgender people and medical experts.

 

Elizabeth Holmes Loses Bid for Bail at Appeals Court

Joel Rosenblatt, Bloomberg

Elizabeth Holmes lost her final request to remain free on bail while she appeals her fraud conviction.

 
Payers
 

Providers brace for financial impacts of Medicaid redetermination

Arielle Dreher, Axios

A surge in the uninsured population from Medicaid redetermination could swamp some health systems that struggled to stay afloat during the pandemic. But experts say it could also translate into a financial boost for networks, if enough individuals find new sources of coverage.

 

Legislators reintroduce bill aimed at easing barriers to virtual mental health care in Medicare

Paige Minemyer, Fierce Healthcare

The bill, co-sponsored by Reps. Doris Matsui, D-California, and Bill Johnson, R-Ohio, would eliminate a requirement that doctors see Medicare beneficiaries in person within six months of a virtual visit for mental and behavioral health concerns, according to an announcement.

 

Insurers, PBMs restrict access to weight loss drugs as demand soars

Nona Tepper, Modern Healthcare

Payers have taken a cautious approach to handling rising demand for the pricey new class of drugs known as glucagon-like peptide agnostics, or GLP-1s.

 

More people want fertility care. Insurance coverage is lagging behind

Tom Murphy, The Associated Press

Infertility, or the inability to get pregnant after a year or more of trying, is a common problem. The federal Centers for Disease Control and Prevention estimates that it affects nearly one in five married girls or women between the ages of 15 and 49. Yet coverage of fertility treatments can be hard to find in many corners of health insurance even as it grows briskly with big employers who see it as a must-have benefit to keep workers.

 

Frank Diamond, Fierce Healthcare

UnitedHealthcare, facing a storm of backlash from docs over its decision to implement a policy that would require prior authorization for some surveillance and diagnostic colonoscopies, is pushing back against the criticisms.

 
Providers
 

Debt Breach Risks $71 Billion in Medicare, Medicaid Pay Delays

Tony Pugh and Ganny Belloni, Bloomberg Law

For hospitals, doctors, and other health-care providers still working to regain patients amid rising labor and supply costs due to Covid-19, a debt ceiling standoff adds unwelcome uncertainty to their usually reliable Medicare reimbursements.

 
Pharma, Biotech and Devices
 

US Challenge to Amgen Deal Threatens Big Pharma Business Model 

Ike Swetlitz, Bloomberg 

US trade regulators' surprise attempt to block a pending drug industry merger is creating alarm that the government will upend a successful business model in the industry.

 

J&J's proposed talc settlement would pay $400 million to US state AGs

Dietrich Knauth, Reuters

Johnson & Johnson has set aside $400 million to resolve U.S. state consumer protection actions as part of its broader $8.9 billion effort to settle claims that its Baby Powder and other talc products cause cancer.

 

Roche says new MS drug shown to reduce brain lesions

Reuters

Roche said on Wednesday that its multiple sclerosis drug candidate, part of a class of compounds that has been linked to cases of liver damage, reduced brain lesions in a mid-stage trial and that no new safety concerns emerged.

 

Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data

Dinesh Nair and Michelle F. Davis, Bloomberg

European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.

 

NIH foundation adds 8 rare diseases to clinical trial portfolio

Max Bayer, Fierce Biotech 

The new priorities announced Tuesday are grouped under the foundation's Bespoke Gene Therapy Consortium, a collaboration with biotechs, pharmas and non-profits to accelerate drug development for rare diseases.

 

Major regulatory changes are coming to pharma in the EU — and industry's weighing in

Karissa Waddick, PharmaVoice

The European Union published a long-awaited proposal that could bring sweeping changes to its pharma sector last month, but the legislative fight has only just begun.

 

Families raised millions and handed rare disease therapies off to biotechs. But companies have backed out

Jared Whitlock, Endpoints News 

In the last 16 months, drugmakers have canceled or paused development on 26 rare disease programs that were financially supported by patient groups, based on an Endpoints News review of public filings and news reports, which was cross-referenced with patient groups.

 

Tests clear recalled Philips sleep apnoea machines of health risks 

Reuters 

Dutch medical devices maker Philips (PHG.AS) said on Tuesday that independent tests have shown that the use of its respiratory devices involved in a major global recall did not cause health risks for patients.

 
Health Technology
 

Google Cloud launches AI tools to accelerate drug discovery 

Ashley Capoot and Annika Kim Constantino, CNBC

Google Cloud on Tuesday launched two new AI-powered tools that aim to help biotech and pharmaceutical companies accelerate drug discovery and advance precision medicine.

 

AI leaders issue a plea to Congress: Regulate us, and quickly

Casey Ross, Stat News

During an extraordinary hearing Tuesday, members of a Senate subcommittee called for aggressive regulation of generative AI tools — and the makers and users of the technologies themselves urged the senators to quickly follow through.

 

General Catalyst leads $50M investment in healthcare AI company

Brock E.W. Turner, Modern Healthcare

Hippocratic AI is the latest entrant in the generative artificial intelligence market as the new company launched Tuesday morning with $50 million in seed funding.

 

Text-only version of this email

WV MORNING CONSULT   HEALTH Essential health care industry news & intel to start your day. MAY 17, 2023 By Ricky Zipp Twitter Email   TODAY'S TOP NEWS * Sen. Bernie Sanders (I-Vt.) plans to use his position as leader of the Senate Health, Education, Labor and Pensions Committee to pursue a nearly $200 billion plan to improve the U.S. health system, including tens of billions of dollars to address health care staffing shortages. Over five years, the plan would provide $130 billion to community health centers and $60 billion to grow the health workforce, with $15 billion earmarked for graduate medical programs, Sanders said in an interview. (Politico) * AstraZeneca PLC said it left the powerful pharmaceutical industry lobbying group PhRMA, following Teva Pharmaceuticals Industries Ltd.'s decision to leave in February and AbbVie Inc.'s exit in December 2022. AstraZeneca said the decision came after reevaluating whether trade group memberships are "productive and effective," stating that the company will continue to lobby state and federal lawmakers but are "changing how we do it." (Stat News) * The 5th U.S. Circuit Court of Appeals will hear oral arguments today for the controversial lawsuit that challenges the Food and Drug Administration's approval of the abortion pill mifepristone, putting the fate of access to the medication in the hands of three judges with a history of supporting abortion restrictions. (The Associated Press) Meanwhile, North Carolina's Republican-controlled state legislature overrode Gov. Roy Cooper's (D) veto of a 12-week abortion ban, allowing the law to now take effect. (Axios) * The higher mortality rate for Black Americans led to 1.63 million excess deaths between 1999 to 2020 compared with white Americans, according to a new JAMA study. Clyde Yancy, an author of the study and chief of cardiology at Northwestern University's Feinberg School of Medicine, said that the high mortality rates have more to do with the United States' history of discrimination than with genetics, adding that it is "very clear that we have an uneven distribution of health." (KFF Health News) Worth watching today: * Financial Times's "U.S. Pharma and Biotech Summit" continues. Today's speakers include Amgen Inc. CEO Robert A. Bradway and Roche Pharmaceuticals CEO Teresa Graham. * The Duke-Margolis Center hosts its in Washington, D.C. Speakers include Elizabeth Fowler, director of the Center for Medicare & Medicaid Innovation, Ashish Jha, the White House's COVID-19 response coordinator, and Meena Seshamani, director of the Center for Medicare. * House Ways and Means Health Subcommittee hearing: "Why Health Care is Unaffordable: Anticompetitive and Consolidated Markets." CHART REVIEW Cancer deaths drop in D.C. Axios Change in cancer death rates by congressional district Change in the number of deaths per 100k residents; 1996-2003 compared to 2012-2020 E -50% -40% -30% -20% KY-05 b Data: American Cancer Society. Note: Death rate is computed as the average of the male and female rates. Map: Erin DavisAxios Visuals A MESSAGE FROM MORNING CONSULT VvV MORNING CONSULT H1 2023 The State of Travel Hospitality A look at the major factors influencing consumers travel behaviors and expectations DOWNLOAD NOW THE STATE OF TRAVEL & HOSPITALITY H1 2023 Morning Consult's semiannual report, The State of Travel & Hospitality, tracks evolving travel trends in the travel & hospitality sector and what they mean for the future of the industry. Download today. WHAT ELSE YOU NEED TO KNOW Coronavirus Moderna hits back at Alnylam's 'baseless' patent infringement claims Zoey Becker, Fierce Pharma After Alnylam levied patent infringement claims against Moderna last year, the mRNA specialist is hitting back. In a pair of countersuits, Moderna claims Alnylam "baselessly seeks to profit" from Moderna's inventions. As COVID-19 recedes, payers face changed coverage landscape Frank Diamond, Fierce Healthcare  There will never be a return to a pre-pandemic normal in terms of what health insurers, self-insured employers and other payers must cover, but they will in some ways be less burdened as COVID-19 recedes, according to Jeff Levin-Scherz, M.D., the population health leader for health and benefits in North America at Willis Towers Watson. AstraZeneca Investors Lose Appeal of Covid Shot Suit's Dismissal Martina Barash, Bloomberg Law  AstraZeneca PLC investors failed to show the drugmaker misled them about its coronavirus vaccine testing process, the Second Circuit affirmed Tuesday. General The one abortion law Democrats aren't rushing to repeal Megan Messerly and Alice Miranda Ollstein, Politico As legislative sessions come to a close, state lawmakers are divided over whether children and teenagers should be able to have an abortion without telling their parents. Pfizer RSV vaccine for infants has 'generally favorable' safety data, FDA staff say Annika Kim Constantino, CNBC The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday when a panel of external advisors to the agency will discuss whether to recommend full approval of the RSV shot. Drug Shortages Near an All-Time High, Leading to Rationing Christina Jewett, The New York Times A worrisome scarcity of cancer drugs has heightened concerns about the troubled generic drug industry. Congress and the White House are seeking ways to address widespread supply problems. Young Americans Are Dying at Alarming Rates, Reversing Years of Progress Janet Adamy, The Wall Street Journal For decades, advances in healthcare and safety steadily drove down death rates among American children. In an alarming reversal, rates have now risen to the highest level in nearly 15 years, particularly driven by homicides, drug overdoses, car accidents and suicides. Comstock Act, 150-year-old law, may determine U.S. access to abortion  Dan Diamond and Ann E. Marimow, The Washington Post  The future of abortion access in the United States may soon depend on how courts interpret a 150-year-old law that hadn't been applied for nearly a century — and whose author originally intended for some abortions to remain legal. Republicans weigh changes to law meant to protect abortion access  Michael Macagnone, Roll Call  The chairman of a House Judiciary subcommittee said Tuesday that Republicans could pursue changes to a 1994 law meant to protect access to reproductive health care clinics. Republican abortion debate inches toward resolution in South Carolina James Pollard, The Associated Press Abortions would be almost entirely banned after about six weeks of pregnancy under a bill debated early into Wednesday morning by the South Carolina House in a development that follows months of Republicans in the chamber insisting instead on a near-total ban that the state Senate recently rejected. Suspected deadly fungal infections linked to surgery in Mexico Lena H. Sun, The Washington Post The CDC issued a travel advisory after five women developed meningitis after surgical procedures in the border city of Matamoros. Walgreens sees benefit from CVS exiting clinical trial business Anjalee Khemlani, Yahoo Finance  Walgreens is already benefiting from CVS winding down its efforts to conduct clinical trials in its retail locations. Chronic pain is more common than diabetes or depression. Better treatments are emerging. Aria Bendix, NBC News People are developing new cases of chronic pain at higher rates than new diagnoses of diabetes, depression or high blood pressure, according to a study published Tuesday. Weight-loss drugs and surgery for kids leave parents with tough decisions  Yuki Noguchi, NPR News New drugs like semaglutide — approved for weight loss under the brand Wegovy — tamp down hunger and boost metabolism; adolescent bariatric surgery achieves similar results. Both treatments were added early this year to the American Academy of Pediatrics' recommended treatment guidelines for children as young as 12 or 13 — acknowledging the increasing threat of the disease in children. Cops say they're being poisoned by fentanyl. Experts say the risk is 'extremely low' Brian Mann, NPR News Police officers regularly report being poisoned or overdosing after encountering trace amounts of fentanyl on the job. Experts say it's not happening. NIH seeks to unlock secrets of how our bodies respond to food Tina Reed, Axios  Federal researchers are launching a major study of how genes, lifestyle and other factors influence how the body responds to diet, to come up with better interventions when it comes to what we eat. The fraught fight to stop the trans healthcare bans Emma Hurt et al., Axios Across the country, Democratic lawmakers in GOP states have struggled to stop an onslaught of bills restricting gender-affirming health care for transgender minors. How a Few Stories of Regret Fuel the Push to Restrict Gender Transition Care  Maggie Astor, The New York Times  In the campaign to ban gender therapies for minors, Republicans have amplified a group of activists who no longer identify as transgender, overriding objections from transgender people and medical experts. Elizabeth Holmes Loses Bid for Bail at Appeals Court Joel Rosenblatt, Bloomberg Elizabeth Holmes lost her final request to remain free on bail while she appeals her fraud conviction. Payers Providers brace for financial impacts of Medicaid redetermination Arielle Dreher, Axios A surge in the uninsured population from Medicaid redetermination could swamp some health systems that struggled to stay afloat during the pandemic. But experts say it could also translate into a financial boost for networks, if enough individuals find new sources of coverage. Legislators reintroduce bill aimed at easing barriers to virtual mental health care in Medicare Paige Minemyer, Fierce Healthcare The bill, co-sponsored by Reps. Doris Matsui, D-California, and Bill Johnson, R-Ohio, would eliminate a requirement that doctors see Medicare beneficiaries in person within six months of a virtual visit for mental and behavioral health concerns, according to an announcement. Insurers, PBMs restrict access to weight loss drugs as demand soars Nona Tepper, Modern Healthcare Payers have taken a cautious approach to handling rising demand for the pricey new class of drugs known as glucagon-like peptide agnostics, or GLP-1s. More people want fertility care. Insurance coverage is lagging behind Tom Murphy, The Associated Press Infertility, or the inability to get pregnant after a year or more of trying, is a common problem. The federal Centers for Disease Control and Prevention estimates that it affects nearly one in five married girls or women between the ages of 15 and 49. Yet coverage of fertility treatments can be hard to find in many corners of health insurance even as it grows briskly with big employers who see it as a must-have benefit to keep workers. Frank Diamond, Fierce Healthcare UnitedHealthcare, facing a storm of backlash from docs over its decision to implement a policy that would require prior authorization for some surveillance and diagnostic colonoscopies, is pushing back against the criticisms. Providers Debt Breach Risks $71 Billion in Medicare, Medicaid Pay Delays Tony Pugh and Ganny Belloni, Bloomberg Law For hospitals, doctors, and other health-care providers still working to regain patients amid rising labor and supply costs due to Covid-19, a debt ceiling standoff adds unwelcome uncertainty to their usually reliable Medicare reimbursements. Pharma, Biotech and Devices US Challenge to Amgen Deal Threatens Big Pharma Business Model  Ike Swetlitz, Bloomberg  US trade regulators' surprise attempt to block a pending drug industry merger is creating alarm that the government will upend a successful business model in the industry. J&J's proposed talc settlement would pay $400 million to US state AGs Dietrich Knauth, Reuters Johnson & Johnson has set aside $400 million to resolve U.S. state consumer protection actions as part of its broader $8.9 billion effort to settle claims that its Baby Powder and other talc products cause cancer. Roche says new MS drug shown to reduce brain lesions Reuters Roche said on Wednesday that its multiple sclerosis drug candidate, part of a class of compounds that has been linked to cases of liver damage, reduced brain lesions in a mid-stage trial and that no new safety concerns emerged. Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data Dinesh Nair and Michelle F. Davis, Bloomberg European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching. NIH foundation adds 8 rare diseases to clinical trial portfolio Max Bayer, Fierce Biotech  The new priorities announced Tuesday are grouped under the foundation's Bespoke Gene Therapy Consortium, a collaboration with biotechs, pharmas and non-profits to accelerate drug development for rare diseases. Major regulatory changes are coming to pharma in the EU — and industry's weighing in Karissa Waddick, PharmaVoice The European Union published a long-awaited proposal that could bring sweeping changes to its pharma sector last month, but the legislative fight has only just begun. Families raised millions and handed rare disease therapies off to biotechs. But companies have backed out Jared Whitlock, Endpoints News  In the last 16 months, drugmakers have canceled or paused development on 26 rare disease programs that were financially supported by patient groups, based on an Endpoints News review of public filings and news reports, which was cross-referenced with patient groups. Tests clear recalled Philips sleep apnoea machines of health risks  Reuters  Dutch medical devices maker Philips (PHG.AS) said on Tuesday that independent tests have shown that the use of its respiratory devices involved in a major global recall did not cause health risks for patients. Health Technology Google Cloud launches AI tools to accelerate drug discovery  Ashley Capoot and Annika Kim Constantino, CNBC Google Cloud on Tuesday launched two new AI-powered tools that aim to help biotech and pharmaceutical companies accelerate drug discovery and advance precision medicine. AI leaders issue a plea to Congress: Regulate us, and quickly Casey Ross, Stat News During an extraordinary hearing Tuesday, members of a Senate subcommittee called for aggressive regulation of generative AI tools — and the makers and users of the technologies themselves urged the senators to quickly follow through. General Catalyst leads $50M investment in healthcare AI company Brock E.W. Turner, Modern Healthcare Hippocratic AI is the latest entrant in the generative artificial intelligence market as the new company launched Tuesday morning with $50 million in seed funding. Opinions, Editorials and Perspectives CDC's new indoor air guidelines are a monumental victory for health  Joseph G. Allen, The Washington Post  We might be on the verge of an indoor air quality revolution, and it could be among the most important public health victories of the 21st century. I'm a Breast Cancer Surgeon. Here's What I Think of the New Screening Guidelines.  Mehra Golshan, The New York Times  When I learned that the U.S. Preventive Services Task Force once again changed its recommendation for when women should begin screening for breast cancer — this time recommending women start at age 40 rather than 50 — I had just finished operating on a 48-year-old African American woman with aggressive breast cancer. My patient had presented to doctors with a painful lump. She didn't think she needed a mammogram for another two years. This email was sent to: [email protected] by: Morning Consult 1025 F Street NW, Suite 800, Washington, DC 20004 |
Show all

The Latest Emails Sent By Morning Consult

More Emails, Deals & Coupons From Morning Consult

Email Offers, Discounts & Promos From Our Top Stores